Cigna Group: Form 10-Q for the period ended Sep 30, 2025
Filed with the SEC on Oct 30, 2025 and accepted by EDGAR at Oct 30, 2025, 16:20 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-07-01 to 2025-09-30 | $69.75bn | us-gaap:Revenues |
| Revenue | 9 months2025-01-01 to 2025-09-30 | $202.43bn | us-gaap:Revenues |
| Cost of revenue | 3 months2025-07-01 to 2025-09-30 | $55.53bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2025-01-01 to 2025-09-30 | $157.20bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2025-07-01 to 2025-09-30 | $3.36bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2025-01-01 to 2025-09-30 | $11.01bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-07-01 to 2025-09-30 | $2.58bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-01-01 to 2025-09-30 | $6.86bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-07-01 to 2025-09-30 | $322.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-01-01 to 2025-09-30 | $950.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-07-01 to 2025-09-30 | $1.97bn | us-gaap:ProfitLoss |
| Net income | 9 months2025-01-01 to 2025-09-30 | $5.01bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2025-07-01 to 2025-09-30 | $6.98 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-01-01 to 2025-09-30 | $17.52 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-07-01 to 2025-09-30 | $7.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-01-01 to 2025-09-30 | $17.65 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-07-01 to 2025-09-30 | 267,530,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-01-01 to 2025-09-30 | 269,527,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-01-01 to 2025-09-30 | $3.45bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 9 months2025-01-01 to 2025-09-30 | $1.22bn | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2025-01-01 to 2025-09-30 | $2.62bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-09-30 | $6.03bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-09-30 | $46.73bn | us-gaap:AssetsCurrent |
| Total assets | At period end2025-09-30 | $157.92bn | us-gaap:Assets |
| Current liabilities | At period end2025-09-30 | $56.45bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-09-30 | $115.91bn | us-gaap:Liabilities |
| Current portion of debt | At period end2025-09-30 | $3.09bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2025-09-30 | $41.80bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001739940-25-000037. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.